Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathways and is used to treat myelofibrosis, polycythemia vera and steroid refractory graft versus host disease in the setting of allogeneic stem cell transplantation.

We describe the pharmacokinetics and pharmacodynamics of ruxolitinib for myelofibrosis, polycythemia vera and steroid refractory graft versus host disease.

We show that the pharmacokinetics and pharmacodynamics are well known, but further research is needed to explain the interindividual variability of the pharmacokinetic variables and to optimize the individual treatment.